ADC Landscape Webinar
The momentum of ADCs has continued to assert its dominance in the oncology field throughout 2023, with a huge influx of new developers entering the space and numerous shifts in focus across payloads, combination trials, and Bispecific ADCs. In our recent webinar, we invited attendees to explore the traditional and novel ADC landscapes to maximize their pipelines and discover new opportunities that show huge potential to accelerate drug development.
We asked:
The total number of ADC programs has more than doubled in the last 2 years, what are the emerging trends from this recent influx of activity?
From Payloads, Linkers, and Targets, to Bispecifics and Combinations, which approaches are seeing the most use and having the most impact across the ADC space?
What were the key highlights and updates for ADC development across 2023?
Our Experts
Jia He
House Speaker
ADC Senior Research Lead
Beacon
Jake Morris
Moderator
Account Manager
Beacon
You May Also Be Interested In…
Where ADC Innovation Is Going: Multispecific & Multipayload Landscapes Unpacked
View Webinar
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
